The Fort Worth Press - Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

USD -
AED 3.672498
AFN 66.148191
ALL 82.068343
AMD 381.699391
ANG 1.790403
AOA 916.99988
ARS 1440.7439
AUD 1.503793
AWG 1.8
AZN 1.699903
BAM 1.664171
BBD 2.013461
BDT 122.170791
BGN 1.66426
BHD 0.376978
BIF 2953.098941
BMD 1
BND 1.288843
BOB 6.933052
BRL 5.406404
BSD 0.999711
BTN 90.668289
BWP 13.203148
BYN 2.923573
BYR 19600
BZD 2.010568
CAD 1.37606
CDF 2239.999697
CHF 0.794545
CLF 0.023284
CLP 913.550023
CNY 7.054499
CNH 7.040365
COP 3807.37
CRC 500.068071
CUC 1
CUP 26.5
CVE 93.823389
CZK 20.672603
DJF 178.023212
DKK 6.351085
DOP 63.501923
DZD 129.675982
EGP 47.454198
ERN 15
ETB 155.594517
EUR 0.85007
FJD 2.255901
FKP 0.748248
GBP 0.746725
GEL 2.703684
GGP 0.748248
GHS 11.496375
GIP 0.748248
GMD 72.999636
GNF 8693.543446
GTQ 7.65801
GYD 209.150549
HKD 7.78138
HNL 26.332494
HRK 6.407598
HTG 130.986011
HUF 327.15099
IDR 16669
ILS 3.214585
IMP 0.748248
INR 90.69645
IQD 1309.604847
IRR 42122.503518
ISK 125.980117
JEP 0.748248
JMD 159.763112
JOD 0.708968
JPY 154.951015
KES 129.000105
KGS 87.45029
KHR 4000.034036
KMF 419.499164
KPW 899.999687
KRW 1467.110041
KWD 0.30672
KYD 0.833099
KZT 515.622341
LAK 21662.809299
LBP 89523.161227
LKR 309.11133
LRD 176.449066
LSL 16.773085
LTL 2.95274
LVL 0.60489
LYD 5.419319
MAD 9.176168
MDL 16.874708
MGA 4456.111092
MKD 52.386565
MMK 2099.265884
MNT 3545.865278
MOP 8.013921
MRU 39.767196
MUR 45.949654
MVR 15.400451
MWK 1733.51826
MXN 17.98899
MYR 4.092499
MZN 63.909588
NAD 16.773085
NGN 1452.389994
NIO 36.792485
NOK 10.13206
NPR 145.069092
NZD 1.724695
OMR 0.384513
PAB 0.999711
PEN 3.366461
PGK 4.248494
PHP 58.825957
PKR 280.165924
PLN 3.588798
PYG 6714.373234
QAR 3.643511
RON 4.328604
RSD 99.80103
RUB 79.247686
RWF 1455.544872
SAR 3.751978
SBD 8.176752
SCR 14.406023
SDG 601.497294
SEK 9.27336
SGD 1.288475
SHP 0.750259
SLE 24.125024
SLL 20969.503664
SOS 570.351588
SRD 38.610012
STD 20697.981008
STN 20.846806
SVC 8.74715
SYP 11056.681827
SZL 16.776148
THB 31.447035
TJS 9.192328
TMT 3.51
TND 2.923658
TOP 2.40776
TRY 42.697297
TTD 6.784997
TWD 31.305503
TZS 2482.501398
UAH 42.255795
UGX 3560.97478
UYU 39.174977
UZS 12094.5509
VES 267.43975
VND 26320
VUV 121.127634
WST 2.775483
XAF 558.147272
XAG 0.01572
XAU 0.000231
XCD 2.70255
XCG 1.801675
XDR 0.695393
XOF 558.147272
XPF 101.477145
YER 238.506089
ZAR 16.78781
ZMK 9001.202967
ZMW 23.168034
ZWL 321.999592
  • SCS

    0.0200

    16.14

    +0.12%

  • GSK

    0.4000

    49.21

    +0.81%

  • NGG

    0.6400

    75.57

    +0.85%

  • BP

    0.0000

    35.26

    0%

  • BCC

    -0.8350

    75.675

    -1.1%

  • AZN

    1.3500

    91.18

    +1.48%

  • RIO

    -0.0800

    75.58

    -0.11%

  • CMSD

    0.0600

    23.31

    +0.26%

  • BCE

    0.1861

    23.58

    +0.79%

  • RYCEF

    0.2200

    14.82

    +1.48%

  • JRI

    0.0435

    13.61

    +0.32%

  • BTI

    0.5700

    57.67

    +0.99%

  • RBGPF

    -3.4900

    77.68

    -4.49%

  • RELX

    0.8500

    41.23

    +2.06%

  • VOD

    0.1950

    12.785

    +1.53%

  • CMSC

    0.0200

    23.32

    +0.09%

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.

Text size:

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."

"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."

AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
[email protected]

SOURCE: Avant Technologies



View the original press release on ACCESS Newswire

C.Dean--TFWP